---
title: Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose
nct_id: NCT00507013
overall_status: COMPLETED
phase: PHASE1, PHASE2
sponsor: CardioDex
study_type: INTERVENTIONAL
primary_condition: Hemostasis,Surgical
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00507013.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00507013"
ct_last_update_post_date: 2008-04-24
last_seen_at: "2026-05-12T06:55:01.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose

**Official Title:** The QuickClose Study: Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose: a Prospective, Non-Randomized Clinical Study

**NCT ID:** [NCT00507013](https://clinicaltrials.gov/study/NCT00507013)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 8
- **Lead Sponsor:** CardioDex
- **Collaborators:** Sheba Medical Center
- **Conditions:** Hemostasis,Surgical
- **Start Date:** 2007-07
- **Completion Date:** 2007-09
- **CT.gov Last Update:** 2008-04-24

## Brief Summary

The QuickClose study is a prospective, non-randomized study, to evaluate the safety and efficacy of the QuickClose device using two different dose types of heat exposure.

Patients undergoing a diagnostic angiogram procedure will be treated with the QuickClose device. Two groups of 20 patients each, will be enrolled consecutively, Group A will complete enrollment before enrollment into Group B begins. Patients will be monitored until 30 days after the procedure

## Detailed Description

The primary safety endpoint is the incidence of major complications related to method for achieving hemostasis at the puncture site. The secondary safety endpoint is the incidence of minor complications related to method for achieving hemostasis at the puncture site. The primary efficacy endpoint are time to hemostasis, time to ambulation and time to discharge . The secondary efficacy endpoints are device and procedure success.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. The patient must be ≥ 18 years of age
2. The patient or guardian must provide written informed consent
3. The patient must be willing to comply with follow-up requirements
4. The patient has no child bearing potential or has a negative pregnancy test within the previous 7 days.
5. Patient is eligible for same day discharge

Procedural Inclusion:

1. A intravascular procedure was preformed using 6 Fr introducer
2. The introducer sheath is located in the common femoral artery

Exclusion Criteria:

1. Manual compression has been preformed on the ipsilateral arterial site within the previous 6 weeks
2. Any closure device has been used on the ipsilateral arterial site within the previous 180 days
3. Any reentry of the ipsilateral site is planned within the next 6 weeks.
4. History of surgical repair of blood vessels of the ipsilateral arterial site
5. Significant bleeding diathesis or platelet dysfunction

   1. Thrombocytopenia (Plt count ≤ 100,000)
   2. Anemia (Hgb ≤ 10mg/dl and/or Hct ≤ 30mg/dl)
6. Has life expectancy of less than 1 year due to terminal illness
7. Currently being treated for an infection
8. Receiving GP 2b/3a inhibitors or requires warfarin therapy within the last 14 days.
9. INR results \> 1.2 on day of procedure
10. Experienced a Myocardial infarction (CK-MB ≥ 2x upper limits of normal) within the previous 72 hours
11. Received thrombolytic within previous 72 hours
12. Patient is currently enrolled in an investigational device or drug study which endpoints have not been met.
13. Absent of pedal pulse
14. Pre-existing autoimmune disease (i.e., Lupus, Addison's Disease, Grave's Disease)
15. Has Body Mass Index(BMI) \<20, or BMI \>40
```

## Arms

- **2** (OTHER)

## Interventions

- **QuickClose device** (DEVICE)

## Primary Outcomes

- **rate of complication** _(time frame: 30 days)_

## Secondary Outcomes

- **time to hemostasis** _(time frame: 30 days)_

## Locations (1)

- The Chaim Sheba M.C., Tel Litwinsky, Israel

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the chaim sheba m.c.|tel litwinsky||israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00507013.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00507013*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*